Hosted on MSN2mon
Eli Lilly to acquire Scorpion for up to $2.5BScorpion's lead drug asset, a mutant-selective PI3Kα inhibitor known as STX-478, is currently in Phase 1/2 testing for the treatment of breast cancer and other solid tumors. Under the deal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback